228 related articles for article (PubMed ID: 20971737)
21. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
Brizzolara A; Benelli R; Venè R; Barboro P; Poggi A; Tosetti F; Ferrari N
Cancer Lett; 2017 Aug; 400():9-17. PubMed ID: 28450158
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of proliferation, invasion, and migration of prostate cancer cells by downregulating elongation factor-1alpha expression.
Zhu G; Yan W; He HC; Bi XC; Han ZD; Dai QS; Ye YK; Liang YX; Wang J; Zhong W
Mol Med; 2009; 15(11-12):363-70. PubMed ID: 19707524
[TBL] [Abstract][Full Text] [Related]
23. Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation.
Sanders AJ; Parr C; Martin TA; Lane J; Mason MD; Jiang WG
J Cell Physiol; 2008 Sep; 216(3):780-9. PubMed ID: 18449907
[TBL] [Abstract][Full Text] [Related]
24. PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells.
El Haibi CP; Sharma PK; Singh R; Johnson PR; Suttles J; Singh S; Lillard JW
Mol Cancer; 2010 Apr; 9():85. PubMed ID: 20412587
[TBL] [Abstract][Full Text] [Related]
25. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
Saleem M; Adhami VM; Zhong W; Longley BJ; Lin CY; Dickson RB; Reagan-Shaw S; Jarrard DF; Mukhtar H
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):217-27. PubMed ID: 16492908
[TBL] [Abstract][Full Text] [Related]
26. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
27. The migration and invasion of human prostate cancer cell lines involves CD151 expression.
Ang J; Fang BL; Ashman LK; Frauman AG
Oncol Rep; 2010 Dec; 24(6):1593-7. PubMed ID: 21042756
[TBL] [Abstract][Full Text] [Related]
28. Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2.
Murillo H; Schmidt LJ; Tindall DJ
Cancer Res; 2001 Oct; 61(20):7408-12. PubMed ID: 11606371
[TBL] [Abstract][Full Text] [Related]
29. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells.
Mabjeesh NJ; Willard MT; Frederickson CE; Zhong H; Simons JW
Clin Cancer Res; 2003 Jul; 9(7):2416-25. PubMed ID: 12855613
[TBL] [Abstract][Full Text] [Related]
30. Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells.
Kiyomiya K; Lee MS; Tseng IC; Zuo H; Barndt RJ; Johnson MD; Dickson RB; Lin CY
Am J Physiol Cell Physiol; 2006 Jul; 291(1):C40-9. PubMed ID: 16467405
[TBL] [Abstract][Full Text] [Related]
31. Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer.
Dong Z; Liu Y; Scott KF; Levin L; Gaitonde K; Bracken RB; Burke B; Zhai QJ; Wang J; Oleksowicz L; Lu S
Carcinogenesis; 2010 Nov; 31(11):1948-55. PubMed ID: 20837598
[TBL] [Abstract][Full Text] [Related]
32. Deregulated matriptase activity in oral squamous cell carcinoma promotes the infiltration of cancer-associated fibroblasts by paracrine activation of protease-activated receptor 2.
Kanemaru A; Yamamoto K; Kawaguchi M; Fukushima T; Lin CY; Johnson MD; Camerer E; Kataoka H
Int J Cancer; 2017 Jan; 140(1):130-141. PubMed ID: 27615543
[TBL] [Abstract][Full Text] [Related]
33. The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells.
Lin J; Adam RM; Santiestevan E; Freeman MR
Cancer Res; 1999 Jun; 59(12):2891-7. PubMed ID: 10383151
[TBL] [Abstract][Full Text] [Related]
34. Endocytic activation and exosomal secretion of matriptase stimulate the second wave of EGF signaling to promote skin and breast cancer invasion.
Ye F; Yuan Z; Tang Y; Li J; Liu X; Sun X; Chen S; Ye X; Zeng Z; Zhang XK; Zhou H
Cell Rep; 2024 Apr; 43(4):114002. PubMed ID: 38547126
[TBL] [Abstract][Full Text] [Related]
35. Effect of AQP9 Expression in Androgen-Independent Prostate Cancer Cell PC3.
Chen Q; Zhu L; Zheng B; Wang J; Song X; Zheng W; Wang L; Yang D; Wang J
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187384
[TBL] [Abstract][Full Text] [Related]
36. Focal adhesion kinase controls aggressive phenotype of androgen-independent prostate cancer.
Johnson TR; Khandrika L; Kumar B; Venezia S; Koul S; Chandhoke R; Maroni P; Donohue R; Meacham RB; Koul HK
Mol Cancer Res; 2008 Oct; 6(10):1639-48. PubMed ID: 18922979
[TBL] [Abstract][Full Text] [Related]
37. Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2.
Cai C; Portnoy DC; Wang H; Jiang X; Chen S; Balk SP
Cancer Res; 2009 Jun; 69(12):5202-9. PubMed ID: 19491261
[TBL] [Abstract][Full Text] [Related]
38. EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance.
Zhang Y; Linn D; Liu Z; Melamed J; Tavora F; Young CY; Burger AM; Hamburger AW
Mol Cancer Ther; 2008 Oct; 7(10):3176-86. PubMed ID: 18852121
[TBL] [Abstract][Full Text] [Related]
39. Genetic reduction of matriptase-1 expression is associated with a reduction in the aggressive phenotype of prostate cancer cells in vitro and in vivo.
Sanders AJ; Parr C; Davies G; Martin TA; Lane J; Mason MD; Jiang WG
J Exp Ther Oncol; 2006; 6(1):39-48. PubMed ID: 17228523
[TBL] [Abstract][Full Text] [Related]
40. Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells.
Puricelli L; Proietti CJ; Labriola L; Salatino M; Balañá ME; Aguirre Ghiso J; Lupu R; Pignataro OP; Charreau EH; Bal de Kier Joffé E; Elizalde PV
Int J Cancer; 2002 Aug; 100(6):642-53. PubMed ID: 12209601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
